Facial Expression Recognition and Mirror Neurons in Parkinson's Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
After few years of evolution, patients with Parkinson's disease may develop apathy, with different degrees of severity. Apathy is characterized by a loss of interest for the others and for activities. The lack of social interactions in these patients may be due to an impairment in decoding emotional facial expression. Indeed, facial expression recognition, which is necessary to understand other's emotional state, requires a subclinical facial mimicking of the expression observed. Yet, one of the clinical signs of PD is amimia.
This study aims to determinate if there is a facial mimicry disorder in PD ( Parkinson's disease )patients with emotional facial expression (EFE) recognition impairment, compared to healthy control subjects. We also want to know if this facial mimicry disorder is primary (subtended by facial mobility impairment, that is to say amimia) or secondary (related to the mirror neuron systems that allows us to activate similar neural networks when observing and feeling a specific emotion)
| Condition | Intervention |
|---|---|
|
Parkinson's Disease |
Behavioral: Emotional facial expression recognition tests |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Do Facial Expression Recognition Disorder and Mirror Neurons Subtend Apathy in Parkinson's Disease? |
- Measurement of facial electromyographic activity during emotional facial expression recognition tests [ Time Frame: at J0 and at J+15 days ] [ Designated as safety issue: Yes ]
- Measurement of facial electromyographic activity during voluntary facial mimicking [ Time Frame: at J0 and at J+15days ] [ Designated as safety issue: Yes ]
- Measurement of facial electromyographic activity during emotional movies viewing [ Time Frame: Made at J0 and at J+15days ] [ Designated as safety issue: Yes ]
- Measurement of Empathy (Baron-Cohen), Apathy (Starkstein) [ Time Frame: Made at J0 and at J+15days ] [ Designated as safety issue: Yes ]
- Measurement of the effect of Levodopa on these parameters [ Time Frame: Made at J0 and at J+15days ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2010 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
-
Behavioral: Emotional facial expression recognition tests
20 patients with an Idiopathic Parkinson's disease
+ 20 paired healthy volunteers (on sex, age, and education)
After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)
Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)
20 patients with an Idiopathic Parkinson's disease
+ 20 paired healthy volunteers (on sex, age, and education)
After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)
Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with idiopathic Parkinson's disease according to UKPDSBB criteria - Men or women aged between 18 to 75 years
- Free from any visio-perceptive disorder (visual acuity and Vitec)
- Affiliated to National Health system
Having given their informed consent
--Healthy controls
- Men or women aged between 18 to 75 years
- Free from any visio-perceptive disorder (visual acuity and Vitec)
- Affiliated to National Health system
- Having given their informed consent
Exclusion Criteria:
- With dementia or with significant dysexecutive disorder (MMS <24, MATTIS< 130)
- With fluctuations (<5 Levodopa intakes / day)
- With severe depression (BDI > 27)
- With psychiatric comorbidities (hallucinations, psychos) evaluated with l'Unified Parkinson's disease Rating Scale part I (UPDRS part I =0)
- With faces processing disorder (Benton < 39)
- Pregnant
- Treatment with deep brain stimulation
- Under guardianship
In excluding period for another study
--Healthy controls
- Suffering of neurological or psychiatric evolutive condition
- With severe depression (BDI > 27)
- With faces processing disorder (Benton < 39)
- Pregnant
- In excluding period for another study
Contacts and Locations| Contact: Patrick LACARIN | 04 73 75 11 95 | placarin@chu-clermontferrand.fr |
| France | |
| CHU Clermont-Ferrand | Recruiting |
| Clermont-FERRAND, France, 63003 | |
| Contact: Patrick LACARIN 04 73 75 11 95 | |
| Principal Investigator: | Ana MARQUES, PH | University Hospital, Clermont-Ferrand |
More Information
No publications provided
| Responsible Party: | Patrick LACARIN, CHU Clermont-Ferrand |
| ClinicalTrials.gov Identifier: | NCT01315405 History of Changes |
| Other Study ID Numbers: | CHU-0090 |
| Study First Received: | February 28, 2011 |
| Last Updated: | March 15, 2011 |
| Health Authority: | France: Ministry of Health |
Keywords provided by University Hospital, Clermont-Ferrand:
|
Emotional facial expression Apathy Mirror neurons |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |
ClinicalTrials.gov processed this record on May 23, 2013